For chronic inflammation‐induced immune surveillance and dysregulation of the immune environment, programmed death‐1 (PD‐1) inhibitors can restrain tumor immune evasion by blocking the PD‐1/PD‐L1 pathway, increasing the intracorporal anti‐tumor immunoreaction.15 This evidence concerns the gene CD274 and neoplasm.